Holen Sie sich die Stockscreener-App
23.14
0.26%
-0.0342
Schlusskurs vom Vortag:
$23.17
Offen:
$23.11
24-Stunden-Volumen:
202.65K
Relative Volume:
0.11
Marktkapitalisierung:
$2.62B
Einnahmen:
$70.92M
Nettoeinkommen (Verlust:
$-342.21M
KGV:
-6.1459
EPS:
-3.7644
Netto-Cashflow:
$-304.30M
1W Leistung:
+1.45%
1M Leistung:
-2.03%
6M Leistung:
-22.06%
1J Leistung:
+14.35%
1-Tages-Spanne:
$23.05
$23.58
1-Wochen-Bereich:
$22.22
$23.84
52-Wochen-Spanne:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
23.14 | 2.62B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - The Globe and Mail
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Viridian Therapeutics Inc (VRDN:UW): Stock Price, Quote and News - BNN Bloomberg
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet
Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm
ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial - The Globe and Mail
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI - The Globe and Mail
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
VRDN Maintained by RBC Capital -- Price Target Raised to $36.00 - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says - marketscreener.com
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership - Stock Titan
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating - Moomoo
Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41 - Moomoo
William Blair Maintains Viridian Therapeutics(VRDN.US) With Buy Rating - Moomoo
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):